<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01081561</url>
  </required_header>
  <id_info>
    <org_study_id>#20090780</org_study_id>
    <nct_id>NCT01081561</nct_id>
  </id_info>
  <brief_title>Collagen Cross-Linking for Keratoconus/Ectasia With and Without Intacs</brief_title>
  <official_title>Randomized Study of Corneal Collagen Cross-Linking With the UV-X System for the Treatment of Keratectasia in Eyes With Intacs Compared to Eyes Without Intacs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yaron S. Rabinowitz M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cornea Genetic Eye Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the efficacy of collagen cross linking for progressive keratoconus
      and ectasia after lasik. It will try and determine which is a more effective treatment:
      collagen cross linking alone or collagen cross linking combined with Intacs, a treatment
      which has already been proven to be effective in decreasing corneal curvature in patients
      with keratoconus.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of UV-X cross linking to halt progression of keratoconus</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine whether UV-X treatment is more effective when combined with Intacs or just UV-X alone</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Keratoconus</condition>
  <condition>Ectasia</condition>
  <arm_group>
    <arm_group_label>Cross-linking</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corneal collagen cross-linking with riboflavin and UVA light</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cross-linking plus INTACS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corneal collagen cross-linking with riboflavin and UVA light plus INTACS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin</intervention_name>
    <description>Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.</description>
    <arm_group_label>Cross-linking</arm_group_label>
    <arm_group_label>Cross-linking plus INTACS</arm_group_label>
    <other_name>Peschke Meditrade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  progressive keratoconus or ectasia

        Exclusion Criteria:

          -  cornea thinner than 400um

          -  K readings greater than 60D

          -  Central corneal scarring
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaron S Rabinowitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornea Genetic Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ezra Maguen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>american eye institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuri Oleynikov, M.D. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornea Genetic Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Salz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laser Eye Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Gaster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornea Eye Institute, Beverly Hills</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Surgery Center of Beverly Hills</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betty Cardenas</last_name>
      <phone>310-423-9640</phone>
      <email>cardenas.b@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Martha Bucaram</last_name>
      <phone>310 4239640</phone>
      <email>bucaramm@cshs.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <last_update_submitted>December 17, 2012</last_update_submitted>
  <last_update_submitted_qc>December 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cornea Genetic Eye Institute</investigator_affiliation>
    <investigator_full_name>Yaron S. Rabinowitz M.D.</investigator_full_name>
    <investigator_title>Yaron S Rabinowitz M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

